Growing knowledge has led to the refinement of the study of SCD, including the development of the SCD-plus criteria that consider the type of cognitive complaints and presence of the apolipoprotein E (APOE) e4 genotype, for example, to improve SCD as a predictor of AD (Jessen et al., 2014). This evidence concerns the gene APOE and Schnyder corneal dystrophy.